Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.59 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889246 | 1.00 | NR1I2 (0.59) | NR1I2CYP2E1HCAR2 | |
| SCHEMBL134310 | 1.00 | NR1I2 (0.59) | NR1I2CYP2E1HCAR2 | |
| SCHEMBL135303 | 1.00 | NR1I2 (0.59) | NR1I2CYP2E1HCAR2 | |
| SCHEMBL134117 | 0.91 | NR1I2 (0.49) | NR1I2CYP2E1 | |
| SCHEMBL101434 | 0.91 | NR1I2 (0.49) | NR1I2CYP2E1 | |
| SCHEMBL132549 | 0.91 | NR1I2 (0.49) | NR1I2CYP2E1 | |
| SCHEMBL173109 | 0.88 | NR1I2 (0.44) | NR1I2CYP2E1HCAR2 | |
| SCHEMBL15233239 | 0.88 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL12949713 | 0.88 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL15498203 | 0.88 | NR1I2 (0.69) | NR1I2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2559691-A1 | Thiophene analogues for the treatment or prevention of Flavivirus infections | Virochem Pharma Inc. (CA) | 2013-02-20 | — | — | EP | claimed |
| EP-2559692-A1 | Thiophene analogues for the treatment or prevention of Flavivirus infections | Virochem Pharma Inc. (CA) | 2013-02-20 | — | — | EP | claimed |
| US-20120301430-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-11-29 | — | — | US | claimed |
| US-8269014-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-09-18 | — | — | US | claimed |
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals ( Canada) Incorporated (CA) | 2012-03-08 | — | — | US | claimed |
| EP-2104674-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Virochem Pharma Inc. (CA) | 2009-09-30 | — | — | EP | claimed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | claimed |
| WO-2008058393-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2008-05-22 | — | — | WO | claimed |
| US-8658674-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658674-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658674-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2104674-B1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| EP-2104674-B1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| EP-2559692-A1 | Thiophene analogues for the treatment or prevention of Flavivirus infections | Virochem Pharma Inc. (CA) | 2013-02-20 | — | — | EP | disclosed |
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals ( Canada) Incorporated (CA) | 2012-03-08 | — | — | US | disclosed |
| US-8003685-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2011-08-23 | — | — | US | disclosed |
| US-8003685-B2 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2011-08-23 | — | — | US | disclosed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | disclosed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | disclosed |
| WO-2008058393-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059170-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885CYP2E1 98/4885HCAR2 4712/4885 |
| US-20120301430-A1 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885CYP2E1 98/4885HCAR2 4712/4885 |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | TTR, ZC3HAV1, IRF3 | NR1I2 388/4885CYP2E1 98/4885HCAR2 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.